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ABSTRACT 
Milk fat is encapsulated in a milk fat globule mem­
brane (MFGM) that contains bioactive glycoproteins 
and glycolipids. The MFGM inhibits infectivity of ro­
tavirus (RV), activity that has been attributed to its 
glycoprotein and carbohydrate components. However, 
previous studies of proteins and oligosaccharides in the 
MGFM have not accounted for all the bioactivity associ­
ated with the complete MFGM. The lipid fraction of the 
MFGM accounts for half of its composition by weight, 
and we postulate that this fraction should be tested by 
itself to determine if it plays a role in antiviral activity. 
Herein, the anti-RV activity of an organic extract of 
MFGM was tested. Natural and whey buttermilk pow­
ders containing bovine MFGM enriched in polar lipids 
were prepared by microfiltration and supercritical fluid 
extraction treatment to reduce the triglyceride content 
of the powders. Lipid fractions were then extracted 
from the MFGM using both single- and dual-phase ex­
traction methods. Whole MFGM and organic extracts 
were screened in MA-104 cells for anti-infective activity 
against a neuraminidase-sensitive rotavirus using a fo­
cus-forming unit assay. Dose-dependent inhibition was 
observed for whole buttermilk and cheese whey MFGM 
against the rotavirus. In general, buttermilk MFGM 
exhibited greater RV percentage inhibition than cheese 
whey MFGM. Organic-soluble anti-RV compounds 
were identified in bovine MFGM. The most active frac­
tion, isolated by dual-phase extraction and iatrobead 
chromatography, was free of proteins and highly non­
polar. Further separation of this fraction in a less polar 
solvent (30:1 chloroform:methanol) resolved at least 5 
lipid-containing compounds, which likely contribute to 
the anti-RV activity associated with bovine MFGM. In 
summary, lipid components associated with MFGM ap­
pear to contribute in large part to the anti-RV activity 
associated with the bovine MFGM. 
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INTRODUCTION 
Within milk, high-melting-point triglycerides, phos­
pholipids, and glycosphingolipids are encased in the 
milk fat globule membrane (MFGM; Keenan and Pat-
ton, 1995). The glycosphingolipids and phospholipids 
account for half of the weight percentage of the mem­
brane and function as intracellular signaling molecules 
in a variety of biological processes, including regulating 
cell growth, development, adhesion, and cross mem­
brane trafficking (Astaire et al., 2003). In addition, 
a variety of bioactive proteins are embedded in the 
MFGM, including mucin 1 (MUC1), xanthine dehy­
drogenase/oxidase (XDH/XO), periodic acid Schiff 
III (PAS III), cluster of differentiation 36 (CD36), 
butyrophilin (BTN), adipophilin, and periodic acid 
Schiff 6/7 (Mather, 2000). There is insufficient informa­
tion on these proteins to characterize their interaction 
with the lipids that surround them, making it difficult 
to ascribe specific functions without the potential inter­
ference of lipids. 
Over the past 2 decades, evidence has accumulated 
from both in vivo and in vitro studies to suggest numer­
ous potential health benefits associated with MFGM 
and its associated proteins and fats, including inhibi­
tion of gastrointestinal pathogens (Sprong et al., 2002; 
Spitsberg, 2005), such as Helicobacter pylori (Hirmo et 
al., 1998; Wang et al., 2001) and rotavirus (RV; New-
burg et al., 1998; Kvistgaard et al., 2004). 
Worldwide, RV infection is the most common cause 
of severe dehydrating gastroenteritis (Ramig, 2004; 
Widdowson et al., 2005). Rotavirus infections are also 
a concern for agricultural production because of their 
high incidence in many species of animals, particularly 
in weanling calves and piglets (Kuhlenschmidt et al., 
1999), resulting in an estimated economic loss of $7 
million each year for producers (House, 1978). Most 
previous studies have focused on the bioactivities of 
lactadherin and MUC1, 2 glycoproteins that are associ­
ated with the MFGM (Kvistgaard et al., 2004). These 
 proteins are thought to bind to pathogens and help 
remove them from the body via the ciliary action of 
the gut (Yolken et al., 1992; Kvistgaard et al., 2004). 
The concentration of lactadherin in human milk varies 
depending on the stage of lactation; concentrations in 
colostrum and mature milk average 139 and 66 μg/ 
mL, respectively (Peterson et al., 1998). Lactadherin 
is resistant to digestion in the stomach because of its 
high degree of glycosylation (Cavaletto et al., 2004). 
Therefore, it passes into the intestine intact, where 
it can serve as a binding site for bacterial and viral 
pathogens (Cavaletto et al., 2004). An epidemiological 
study of infants infected with human RV showed that 
infants consuming human milk with a mean lactadherin 
concentration of 48.4 μg/mL did not exhibit symptoms 
of RV infection, whereas infants ingesting human milk 
with a mean concentration of 29 μg/mL were symp­
tomatic for RV infection (Newburg et al., 1998). 
Using an in vitro focus-forming unit (FFU) assay, 
Kvistgaard and colleagues (2004) found that 20 μg 
of human lactadherin/mL inhibited RV infectivity by 
50% in Caco-2 cells infected with the WA strain of 
human RV. In addition, they quantified and isolated 
bovine milk lactadherin. Bovine milk lactadherin con­
centrations were comparable to those in human milk; 
however, isolated bovine lactadherin did not inhibit in­
fectivity of neuraminidase-sensitive or neuraminidase­
insensitive strains of RV (Kvistgaard et al., 2004). This 
led the authors to propose that other components of 
the bovine MFGM could be responsible for its anti-RV 
activity. Indeed, anti-RV components were identified in 
whole bovine MFGM and macromolecular whey pro­
teins (MMWP). Bovine mucin, MUC1, is among the 
major components of MFGM and MMWP. It is a high­
molecular-weight, heavily glycosylated protein that ex­
ists in a viscous gel in vivo (Mather, 2000). As a result, 
MUC1 binds to and sequesters pathogenic microorgan­
isms, such as RV and Escherichia coli, thus inhibiting 
their ability to damage the gut epithelium (Schroten 
et al., 1992; Yolken et al., 1992). When MUC1 isolated 
from bovine MFGM was tested for anti-RV activity in 
an FFU assay, a concentration of 6.3 μg of MUC1/ 
mL reduced RV infectivity by 62.5% (Kvistgaard et al., 
2004). In human milk, the oligosaccharides contained 
on MUC-1 include fucose, N-acetylgalactosamine, N­
acetylglucosamine, galactose, and sialic acid. The N-
linked carbohydrate moieties that contain sialic acid at 
their nonreducing end appear to be responsible for the 
virus-inhibitory activity (Yolken et al., 1992; Newburg 
et al., 1998). A subsequent study identified immuno­
globulin as the primary anti-RV factor in the MMWP 
(Bojsen et al., 2007). 
In the current study, the potential for MFGM to 
inhibit RV infection was investigated, because compo­
nents of bovine (Kvistgaard et al., 2004) and human 
(Newburg et al., 1998) MFGM have been shown to 
exert anti-RV activity. We compared MFGM isolated 
from buttermilk or cheese whey buttermilk by microfil­
tration and supercritical fluid extraction (SFE). This 
process selectively extracts triglycerides, which leads to 
enrichment of polar and more complex lipids in the 
MFGM (Astaire et al., 2003). This extraction method 
also results in the selective fractionation of various 
lipids without the use of conventional toxic solvents 
(Astaire et al., 2003). Using buttermilk as a source 
for these lipids as viral inhibitors is a sound strategy 
considering its unique properties as a functional food 
ingredient and its low cost and availability (Walstra et 
al., 1999; USDA-NASS, 2001). We hypothesized that 
MFGM isolated by SFE would inhibit RV infectivity 
and that this effect would be due, in part, to the en­
riched lipid components. 
MATERIALS AND METHODS 
Concentration of MFGM in Natural 
and Whey Cream Buttermilks 
Milk (500 L) for each batch of buttermilk was ob­
tained from the Cal Poly Dairy Farm (San Luis Obispo, 
CA). The skim milk was separated from the cream by 
a pilot-plant cream separator (DeLaval, Kansas City, 
MO). Whey cream for this experiment was produced 
and donated by Hilmar Co. (Hilmar, CA) and 3 batches 
of cream (120 L) were used. The cream was treated in 
the pilot plant at Cal Poly and subjected to regular 
pasteurization: 77.5°C (172°F) for 15 s. Buttermilk 
was pasteurized before storage at 75°C (169°F) for 15 
s. The cream was processed into butter at 12°C using 
a continuous churn (Egli Co., Gumligen, Switzerland), 
and buttermilk and whey buttermilk were collected. 
Buttermilk for each sample was recovered in milk cans, 
small fat grains or aggregates were removed by filtra­
tion through cheese cloth, and the resulting buttermilk 
was passed through the cream separator again. The 
buttermilks were stored overnight at 4°C until mem­
brane filtration was performed. 
A pilot-plant scale system (R-12 model, GEA-Niro 
Filtration, Hudson, WI) with 2 spiral-wound polymeric 
membranes fitted in parallel on the module (10 kDa 
molecular mass cutoff, 11.33 m2 total surface area) was 
used to remove most of the mineral salts, lactose, and 
free oligosaccharides. The process was carried out at 
25°C; the trans-membrane pressure was 600 kPa, and 
the feed pump, attached to a frequency drive, was oper­
ated at 35 Hz. Microfiltration was conducted until a 10­
fold volumetric concentration factor was reached. Di­
afiltration was done while continuously adding purified 
 water at 25°C to the feed tank to replace the removed 
permeate until a 5-fold diafiltration factor was reached. 
In each step of the filtration, samples of retentates were 
collected for composition. The final retained fractions 
from all experiments were spray-dried (NiroFilterlab 
Spray-Drier, Hudson, WI) using 3,500 kPa of pressure, 
and inlet and outlet air temperatures of 175°C and 
90°C, respectively, to obtain buttermilk powder (BM) 
and cheese whey buttermilk powder (CW). All runs 
were performed in triplicate. 
Each buttermilk powder was submitted to SFE to 
remove residual triglycerides from the samples. The 
SFE system and components were acquired from Thar 
Designs Inc. (Pittsburgh, PA), including the 500-mL 
sample vessel, the model P-50 high-pressure pump, the 
automated back pressure regulator (model BPR-A­
200B), and the PolyScience water bath and pump unit 
(model 9505; PolyScience, Niles, IL). Circulated deion­
ized water at 3°C was used to cool different zones in the 
SFE apparatus. Carbon dioxide tanks were filled and 
inspected by A&R Welding Supply (San Luis Obispo, 
CA). The system conditions were controlled manually 
by Windows 2000-based software (Hewlett-Packard, 
Palo Alto, CA). Approximately 200 g of each sample 
was submitted to 3 extraction cycles using the follow­
ing conditions: 1,500 g of CO2 at a flow rate of 20 g/ 
min, extraction pressure of 35 MPa, and extraction and 
collection temperatures of 50°C. The SFE trials were 
done in triplicate. All the powders were stored in a 
humidity-controlled chamber at 10°C. 
Organic Extraction of Lipids from MFGM 
Single-Phase Lipid Extraction and Thin Layer 
Chromatography. A lipid extraction was performed 
on each MFGM-enriched powder using the method of 
Svennerholm and Fredman (1980). Briefly, each pow­
der (75 mg) was suspended in water (0.75 mL) and 
vigorously mixed. While mixing, methanol (2 mL) was 
slowly added followed by chloroform (1 mL) to make 
a chloroform:methanol:water mixture of 1:2:0.75. This 
mixture was centrifuged (1,000 × g, 5 min, 4°C), the 
pellet discarded, and the supernatant collected. Por­
tions of the supernatant were evaporated and suspended 
in either solvent (thin layer chromatography, TLC) or 
minimal essential medium (MEM; focus-forming unit) 
assays. Lipids were separated by silica gel TLC using a 
55:45:10 ratio of chloroform to methanol to water. Lip­
ids were fluorescently detected with primulin (White et 
al. 1998) and carbohydrates were detected with orcinol 
in sulfuric acid. Lactose, cholesterol, and the ganglio­
side GM3 were run as standards. 
Dual-Phase Lipid Extraction and Iatrobead 
Chromatography. To better separate the lipid com­
ponents of the MFGM, a dual-phase lipid extraction 
was performed on each powder (Folch et al., 1957) fol­
lowed by chromatography. Milk fat globule membrane 
(1 g) was suspended in 10 mL of water and mixed. 
While mixing, methanol (16.65 mL) was slowly added 
followed by chloroform (33.33 mL). The mixture was 
centrifuged (1,000 × g, 10 min, 4°C), producing an 
aqueous upper layer, a white interface, and a lower 
chloroform layer. The upper aqueous layer was removed 
and the lower chloroform layer was collected by care­
fully inserting a Pasteur pipette through the interface 
layer. The remaining interface layer was extracted 2 
times by adding water (4.5 mL) followed by 22.5 mL 
of a chloroform:methanol (2:1) solution. After cen­
trifugation, the upper layer was combined with the 
first aqueous layer and the lower layer was combined 
with the first chloroform layer. The combined upper 
layer was concentrated by rotary evaporation to 16 mL, 
and 80 mL of a chloroform:methanol (2:1) solution was 
added, the mixture centrifuged as above, and the up­
per and lower layers collected. Likewise, the combined 
lower layers from the first extraction were evaporated 
to dryness, suspended in 6 mL of water, and then 30 
mL of a chloroform:methanol (2:1) solution was added. 
After centrifugation, all of the upper and lower layers 
were separately combined. Then, the combined aqueous 
layer was concentrated by rotary evaporation to 10 mL 
and the lower organic layer was evaporated to dryness. 
For initial separation of lipids, the organic phase 
was applied to an iatrobead column equilibrated in 
a chloroform:methanol (95:5) solution and eluted us­
ing modifications of a previously described procedure 
(Rolsma et al., 1998). Briefly, the dried organic layer 
(1 g of MFGM equivalent) was dissolved in 5 mL of 
a chloroform:methanol (4.5:1) solution and centrifuged 
to remove any precipitate. The supernatant was ap­
plied to the iatrobead column and eluted with a 4.5:1 
chloroform:methanol solution; nine 100-mL fractions 
were collected. The eluant was then changed to a 
1:1 chloroform:methanol solution and seven 100-mL 
fractions were collected. All fractions were dried by 
rotary evaporation, the 9 samples eluted with chlo­
roform methanol 4.5:1 were suspended with 1 mL of 
chloroform:methanol 4.5:1, and the 7 fractions eluted 
with chloroform:methanol 1:1 were suspended with 1 
mL of chloroform:methanol 1:1. Portions were analyzed 
by TLC, SDS-PAGE, and FFU assays. 
SDS-PAGE Separation of MFGM. Samples 
from both single- and dual-phase extractions were 
dried under nitrogen in microfuge tubes followed by 
addition of 2.5 μL of 4× NuPage sample buffer (Invit­
rogen Inc., Carlsbad, CA), 6.5 μL of water, and 1 μL of 
β-mercaptoethanol. The tubes were heated at 70°C for 
10 min and, after cooling, 10 μL of the sample was ap­
  
plied to a NuPage 10% BisTrispolyacrylamide gel (In­
vitrogen Inc.) and separated by electrophoresis at 200 
V for 50 min. SeeBlue molecular weight standards were 
obtained from Invitrogen Inc., and gels were stained 
with Coomassie Blue to visualize proteins. 
Rotavirus Preparation and FFU Assay 
To assess the anti-RV potential of MFGM, in vitro 
studies were performed using MA-104 cells derived 
from embryonic African green monkey kidney cells 
(BioWhittaker, Walkersville, MD), as previously de­
scribed (Rolsma et al., 1994; Andres et al., 2007). A 
neuraminidase-sensitive, Group A porcine RV strain 
(OSU-RV) serotype P9[7]G5 was propagated in MA­
104 cells, purified as described Rolsma et al. (1994), 
and used for the in vitro experiments. 
An FFU assay to measure RV infectivity in the pres­
ence or absence of MFGM fractions was performed 
as described previously (Rolsma et al., 1998). Briefly, 
125 μL containing the desired amount of MFGM frac­
tion in MEM or MEM alone was mixed with an equal 
volume of RV containing approximately 1,000 FFU 
of infectious activity. This inhibitor-RV mixture was 
incubated for 30 min at 23°C, before applying 100 μL 
to duplicate wells in 24-well plates containing confluent 
MA-104 cell monolayers that had been rinsed free of 
serum with PBS. After adsorption to the MA-104 cell 
layer for 30 min at 37°C, the RV-MFGM inoculum was 
removed. After rinsing the cell layer with PBS, MEM 
without serum was added to each well and the plate 
was incubated at 37°C for 16 to 18 h. Immunochemical 
detection of rotavirus infectivity was performed as de­
scribed (Rolsma et al., 1998). Results for inhibition by 
single- or dual-phase extracts are expressed as relative 
to the total weight of lipids isolated from the MFGM 
powders. 
Statistical Analysis 
Statistical analyses were performed using the PROC 
GLM (generalized linear model) procedure within SAS 
(version 9.2, SAS Institute Inc., Cary, NC) with a post 
hoc LSD test using Fisher’s least significant difference 
test to evaluate the effect of treatment. Statistical 
significance was defined as P < 0.05. All data are ex­
pressed as means ± SEM. 
RESULTS 
Composition of the BM and CW Powders 
Used to Isolate MFGM 
The major components of the buttermilk powders af­
ter SFE are shown in Table 1. Total solids, protein, fat, 
and ash contents were measured. The phospholipids are 
listed separately, but were part of the total fat in the 
sample. The observed difference in protein:fat ratio of 
BM compared with CW has been discussed elsewhere 
(Astaire et al., 2003; Gallier et al., 2010) and seems to 
be a result of how the combination of processes act upon 
the different substrates. For example, casein-containing 
BM appeared to retain more total lipids (including 
triglycerides), whereas the whey-cream buttermilk 
seemed to preferentially attach to phospholipids and 
whey protein aggregates. The source of the whey pro­
tein aggregates is currently not known, but they may 
be produced during processing. 
Comparison of BM and CW Powders 
on Anti-RV Infectivity 
Both whole BM and CW powders containing MFGM 
inhibited the infectivity of the neuraminidase-sensitive 
OSU-RV strain in a dose-dependent manner, at doses 
as low as 0.1 mg/mL (Table 2). Furthermore, 94% in­
hibition of RV infectivity was observed with 10 mg/mL 
BM MFGM and 81% inhibition was found with 13 mg/ 
mL CW MFGM. 
Isolation of MFGM Lipids by Single-Phase 
Extraction and Screening for Anti-RV Activity 
Organic solvent extraction of MFGM using a single-
phase extraction procedure (Svennerholm and Fred-
man, 1980) was performed to isolate lipid components 
of the MFGM and to evaluate their anti-RV activity. 
Table 1. Composition of buttermilk and whey buttermilk powders used for isolation of milk fat globule 
membrane 
Powder1 
TS2 
(% DM) 
Protein 
(% of TS) 
Ash 
(% of TS) 
Fat 
(% of TS) 
SFE-BM 
SFE-CW 
94.5 
95.0 
61.5 
72.7 
4.5 
3.3 
26.5 (12% PL)3 
20.5 (12.1% PL) 
1SFE-BM = supercritical fluid extracted (CO2)-buttermilk powder; SFE-CW = supercritical fluid extracted 
 
(CO2)-cheese whey cream buttermilk powder.
 

2Lactose makes up difference in weight to equate to total solids.
 

3Phospholipids (PL) are part of the total lipids.


  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Effect of exposure to whole milk fat globule membrane 
(MFGM) isolated from either buttermilk (BM) or cheese whey (CW) 
on the infectivity of the neuraminidase-sensitive rotavirus strain 
(OSU-RV)1 
% of MEM 
Item control 
MEM control 100 ± 2.3a 
BM MFGM dose 
0.1 mg/mL 69 ± 3.0b 
0.7 mg/mL 38 ± 4.0c 
1.4 mg/mL 30 ± 7.8c 
3.4 mg/mL 11 ± 4.8d 
10.0 mg/mL 6 ± 2.1d 
17.0 mg/mL 5 ± 0.5d 
CW MFGM dose 
0.1 mg/mL 63 ± 5.0b 
0.5 mg/mL 42 ± 4.0c 
1.2 mg/mL 38 ± 3.5cd 
2.6 mg/mL 30 ± 5.9cde 
7.8 mg/mL 25 ± 3.2de 
13.0 mg/mL 19 ± 0.5e 
a–eMeans with different superscripts differ at P < 0.05.


1Percentage infectivity relative to that of minimal essential medium 
 
(MEM) control measured using focus-forming unit assay; means ± 
 
SEM; n = 4 wells per dose.
 

Separation by TLC of single-phase extracts of BM and 
CW MFGM lipids is shown in Figure 1. Both MFGM 
sources contained some residual lactose and, although 
the lipid separation profiles were similar, BM MFGM 
contained several glycolipids in higher amounts than 
did CW MFGM (arrows). 
The single-phase organic extract was screened for 
anti-RV activity in the FFU assay (Table 3), and the 
data indicate that the organic solvent extract retained 
the inhibitory activity. Compared with whole MFGM, 
the BM MFGM organic extract dose-dependently re­
duced OSU-RV infectivity over a range of 0.2 to 3.0 
mg/mL of the total weight of lipids isolated from the 
BM MFGM powder equivalents, although no further 
reduction was observed between 3 and 10 mg/mL 
(Table 3). The organic extract of CW MFGM displayed 
a similar trend. The results of initial fractionation ex­
periments demonstrated that virus inhibitory activity 
was recovered in the organic solvent extract (Table 3), 
suggesting that MFGM lipids may be responsible for 
the inhibitory activity. 
Further Purification of Lipids by Dual-Phase 
Extraction and Screening for Anti-RV Activity 
Although the single-phase organic extract of the 
MFGM showed anti-RV activity, the single-phase proce­
dure was insufficient to remove proteins that could con­
tribute to antiviral activity, as shown in Figure 2. Both 
BM and CW MFGM were subjected to a dual-phase 
organic (Folch) extraction (Folch et al., 1957). The SDS­
PAGE separation of the 2 lipid extraction methods of 
Figure 1. Thin layer chromatographic (TLC) separation of but­
termilk (BM) and cheese whey (CW) milk fat globule membrane 
(MFGM). Single-phase organic extracts of BM MFGM (lane 1) and 
CW (lane 2), 0.3 mg of dry weight equivalent of each, were separated 
by silica gel TLC using chloroform:methanol:water (55:45:10). Lipids 
were fluorescently detected with primulin (circled bands) and carbo­
hydrates were detected with orcinol in sulfuric acid. Lactose (22 nmol, 
lane 3), cholesterol (13 nmol, lane 4), and ganglioside GM3 (10 nmol, 
lane 5) were run as standards. Arrows indicate orcinol-staining bands 
that were enriched in BM MFGM compared with CW MFGM. This 
image is representative of several experiments. 
BM MFGM (left panel) and CW MFGM (right panel) 
are compared in Figure 2. Whole MFGM (lane 2) was 
compared with dual-phase (lanes 3–6) and single-phase 
(lane 7) extractions for each. Protein was detected in 
the organic extract of the single-phase extraction (lane 
7) and in the aqueous phase of the dual-phase extrac­
tion (lane 3). Several proteins were seen in the aqueous 
phase or interface of the BM MFGM. These proteins 
included those with molecular weights >198 kDa and 
approximately 120, 95, 70, 20, and 14 kDa. Based on 
reported molecular weights of MFGM proteins (Mather, 
2000), the top 4 bands likely correspond to MUC1 
(170–220 kDa, depending on glycosylation), XDH/XO 
(146 kDa), PAS III (95–100 kDa), and CD36 (76 kDa) 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Effect of a single-phase organic extraction on the anti-
infective activity of milk fat globule membrane (MFGM) isolated 
from buttermilk (BM) or cheese whey (CW) against a neuraminidase­
sensitive rotavirus strain (OSU-RV)1 
% of MEM 
Item control 
MEM control 100 ± 2.4a 
BM MFGM dose2 
0.2 mg/mL 70 ± 14.2b 
0.8 mg/mL 42 ± 7.7c 
1.6 mg/mL 30 ± 1.5cd 
3.0 mg/mL 15 ± 1.2d 
10 mg/mL 12 ± 3.0d 
CW MFGM dose2 
0.2 mg/mL 68 ± 20b 
0.8 mg/mL 49 ± 10.1bc 
1.6 mg/mL 20 ± 0cd 
3.0 mg/mL 22 ± 3.8d 
10.0 mg/mL 29 ± 1.5cd 
a–dMeans with different superscripts differ at P < 0.05.


1Percentage infectivity relative to that of minimal essential medium 
 
(MEM) control measured using focus-forming unit assay; mean ± 
 
SEM; n = 4 to 6 wells per dose.
 

2Relative to the total weight of lipids isolated from the MFGM pow­

ders. 
or BTN (66–67 kDa), although this was not verified 
by sequencing. The 2 lower molecular weight bands are 
unknown, but could correspond to whey proteins such 
as β-LG (18.4 kDa) and α-LA (14 kDa). However, pro­
tein was absent from the organic layer of the dual-phase 
extraction for both BM and CW MFGM (lane 4). 
The aqueous and organic phase extracts of the 
MFGM were screened in the FFU assay to differentiate 
the anti-RV activity of the protein and lipid compo­
nents, respectively (Table 4). The organic phase re­
tained the anti-RV activity, whereas the aqueous phase 
did not significantly inhibit RV at any concentration 
tested. These results agreed with the initial hypothesis 
that lipids are the major component responsible for the 
antiviral activity of MFGM. 
Separation of Polar and Nonpolar Lipids 
of the Dual-Phase Organic Extract 
and Screening for Anti-RV Activity 
The organic extract obtained from the dual-phase 
extraction method was separated into relatively non­
polar (4.5:1) to polar (1:1) chloroform:methanol frac­
tions by iatrobead chromatography. The resulting 
fractions were analyzed by TLC (Figure 3) and then 
screened in the FFU assay (Table 5). The top 3 gly­
colipid bands (numbered top to bottom as seen in the 
starting material, Figure 3, lane 1) contained in the 
BM MFGM were highly nonpolar and eluted from the 
iatrobead column in fraction 1. Fractions 2 through 5 
contained varying proportions of bands 3 through 6; 
very little of the MFGM glycolipids eluted after frac­
tion 5. When the iatrobead elution solvent was changed 
to 1:1 (chloroform:methanol), an additional 5 bands 
were eluted, several of which were highly glycosylated 
(orcinol staining). 
As shown in Table 5, most of the anti-RV activity of 
the lipids isolated from the BM MFGM powder eluted 
in nonpolar fraction 1, although the other fractions in­
hibited, on average, 50% of the RV infectivity compared 
with the MEM control. To further separate the lipid 
components in this fraction containing the highest level 
of anti-RV activity, fraction 1 from the iatrobead col­
umn was separated by silica gel high-performance TLC 
using a 30:1 (chloroform:methanol) solvent (Figure 4). 
In this solvent system, the active fraction separated into 
at least 5 primulin-staining (lipid-containing) bands. 
DISCUSSION 
Previous studies have identified glycoprotein compo­
nents of bovine (Kvistgaard et al., 2004; Kuchta et al., 
2012; Le et al., 2012) and human (Newburg et al., 1998) 
MFGM with anti-RV activity; however, little attention 
has been focused on the lipid components of the MFGM. 
The lipids that make up the MFGM include phosphati­
dylcholine, phosphatidyl-ethanolamine, sphingomyelin, 
phosphatidylinositol, phosphatidylserine, and other 
glycosphingolipid or phospholipid components in trace 
amounts, such as gangliosides, sphingosine, and cerami­
des (Hamosh et al., 1999; Parodi, 1999). We undertook 
this study of the lipid component of the MFGM based 
on the results of several clinical and laboratory investi­
gations supporting antiviral and antimicrobial actions 
of milk fats (Koopman et al., 1984; Hamosh, 1991; 
Isaacs and Thormar, 1991; Hamosh et al., 1999; Sprong 
et al., 2001). First, a prospective study of children over 
the age of 1 yr found that those consuming low fat milk 
as their only milk source in the 3 wk before illness were 
at 5 times the risk of requiring a doctor’s visit for acute 
gastrointestinal illness compared with children drinking 
only whole milk during the same period (Koopman et 
al., 1984). This increased risk could not be explained by 
numerous potentially confounding variables or potential 
biases, nor did it vary by the children’s age (Koopman 
et al., 1984). Second, milk fat glycosphingolipids and 
triglycerides, particularly those containing C10:0 and 
C12:0 fatty acids, have been shown to protect against 
foodborne gastroenteritis (Sprong et al., 2001). These 
fatty acids, which appear to have both antimicrobial 
and antiviral activities, may be native in milk or may 
be produced within the gastrointestinal tract as prod­
ucts of digestion (Hamosh, 1991; Isaacs and Thormar, 
1991; Le et al., 2012). Finally, we have shown that gan­
gliosides, which are a minor component of the MFGM, 
are present in neonatal piglet intestine and serve as 
 Figure 2. Sodium dodecyl sulfate-PAGE of milk fat globule membrane (MFGM) extracts. The MFGM isolated from buttermilk (BM, left 
panel) and cheese whey (CW, right panel) were separated on a 10% SDS-PAGE gel and stained with Coomassie blue to visualize proteins. In 
each panel, lane 1 = molecular weight standard, 10 μL; lane 2 = whole MFGM, 0.5 mg of original dry weight equivalent; lane 3 = dual-phase 
aqueous extract, 5 mg of original dry weight equivalent; lane 4 = dual-phase organic extract, 2 mg of original dry weight equivalent; lane 5 = 
iatrobead fraction 4.5:1 (1), 25 mg of dry weight equivalent; lane 6 = dual-phase extraction interface, 0.057 mg equivalent; lane 7 = single-phase 
organic extract, 0.5 mg equivalent. Dual phase (lanes 3–6) was compared with single-phase (lane 7) extraction. This is image is representative 
of several experiments. 
specific receptors for sialic acid–dependent group A 
porcine RV attachment to intestinal epithelial cells 
(Rolsma et al., 1994, 1998). The 2 major monosialogan­
gliosides both possessed a sialyllactose oligosaccharide 
moiety characteristic of GM3 gangliosides; however, 
each ganglioside differed in the type of sialic acid resi­
due it contained (Rolsma et al., 1998). For example, 
an N-glycolylneuraminic acid moiety was found in the 
more polar porcine GM3, whereas the less polar GM3 
species contained N-acetylneuraminic acid. Both the N­
glycolylneuraminic acid GM3 and N-acetylneuraminic 
acid GM3 displayed dose-dependent inhibition of virus 
binding to cells (Rolsma et al., 1998). 
The results herein demonstrated that whole bovine 
MFGM effectively inhibited a neuraminidase-sensitive 
strain OSU-RV in vitro. The MFGM isolated from ei­
ther buttermilk or cheese whey was effective at inhibit­
ing RV infectivity. However, when BM and CW MFGM 
were tested at similar concentrations, the BM was more 
effective than CW MFGM at inhibiting RV infectivity, 
which may reflect the greater complexity of the fatty 
acid composition of BM MFGM. In particular, glycolip­
ids are more abundant and diverse in BM than in CW 
MFGM (Gallier et al., 2010). 
To determine the potential for lipids associated with 
the MFGM to inhibit RV infectivity, the MFGM prepa­
rations were subjected to single and double organic 
phase extractions. The extract resulting from a single-
phase extraction was enriched in polar lipids, but also 
contained some proteins. Although the extract retained 
the ability to inhibit RV in the FFU assay, this activity 
could not be solely attributed to the lipid components. 
Thus, a dual-phase extraction procedure was applied 
that separated the lipid components from the proteins, 
which were recovered in the aqueous phase and at the 
interface between the phases. When the lipid and aque­
ous phases were compared, all anti-RV activity was 
recovered in the lipid phase, whereas the aqueous phase 
did not exert any anti-RV activity. This observation 
was consistent with that of Kvistgaard and colleagues 
(2004), who found that bovine lactadherin did not in­
hibit RV after it was purified from the MFGM. The 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ability of bovine lactadherin to exert its action might 
be dependent upon its structural conformation when it 
is present within the MFGM and that conformation is 
lost upon its isolation. One such example may be the 
activity of α-lactalbumin in the presence of oleic acid to 
form HAMLET or BAMLET (human, or bovine, alpha­
lactalbumin made lethal to tumor cells), and a further 
formation of annular oligomers with phospholipids that 
may explain its function (Baumann et al., 2012). 
To further separate the lipids present in the dual-phase 
extraction, the protein-free lipid extract with anti-RV 
activity was applied to an iatrobead column, and lipids 
were eluted in a stepwise fashion moving from relatively 
nonpolar to more polar solvents. The fraction with the 
greatest anti-RV activity eluted from the column in the 
first fraction in a 4.5:1 chloroform:methanol solvent, 
suggesting that it was relatively nonpolar. The lipids 
in this fraction inhibited 95% of the RV infectivity in 
the FFU assay. Further TLC separation of this fraction 
using a nonpolar solvent, 30:1 chloroform:methanol, 
resolved at least 5 lipid-containing compounds less 
polar than simple gangliosides and phospholipids. It is 
unclear if the SFE treatment would have made a differ­
ence because it removed a large part of nonpolar lipids. 
The current study demonstrates that it is the lipid 
component of the MFGM that has anti-RV activity.
This is consistent with some reports in the literature 
that suggest that milk fat sphingolipids and triglycer-
Table 4. Effect of dual-phase organic extraction on the anti-infective 
activity of milk fat globule membrane (MFGM), isolated from cheese 
whey (CW) or buttermilk (BM) against a neuraminidase-sensitive 
rotavirus strain (OSU-RV)1 
% of MEM 
Item control 
MEM control 100 ± 2.0a 
CW organic extract dose2 
0.8 mg/mL 
2.0 mg/mL 
6.0 mg/mL 
10.0 mg/mL 
CW aqueous extract dose2 
99 ± 35.5a 
34 ± 16.5b 
13 ± 4.5b 
13 ± 2.0b 
0.8 mg/mL 113 ± 12.0a 
2.0 mg/mL 81 ± 30a 
6.0 mg/mL 109 ± 15.0a 
10.0 mg/mL 86 ± 15.0a 
MEM control 100 ± 13.0a 
BM organic extract dose2 
0.2 mg/mL 
5.0 mg/mL 
BM aqueous extract dose2 
82 ± 7a 
26 ± 7b 
20 mg/mL 63 ± 1a 
a,bMeans within MFGM source (CW or BM) with different super­
scripts differ at P < 0.05.


1Percentage infectivity relative to that of minimal essential medium 
 
(MEM) control measured using focus-forming unit assay; means ± 
 
SEM of duplicate wells per dose.
 

2Relative to the total weight lipids isolated from the MFGM powders. 
Figure 3. Thin layer chromatographic (TLC) separation of dual-phase extraction of both powders enriched in milk fat globule membrane, 
natural buttermilk (BM MFGM) and cheese whey-cream buttermilk (CW MFGM), and fractions eluted from the iatrobead column. Whole 
BM MFGM (lane 1) and iatrobead fractions (1% of each fraction volume) were applied and separated by silica gel high-performance TLC using 
chloroform:methanol:water (60:40:9) as the solvent. Lipids were fluorescently detected with primulin (circled bands) and carbohydrates were 
detected with orcinol in sulfuric acid. Lactose and ganglioside GM3 (lane 11) were run as standards. This image is representative of several 
experiments. 
  
 
Figure 4. Thin layer chromatographic (TLC) separation of frac­
tion 1 from the iatrobead column chromatography of dual-phase ex­
tract of buttermilk milk fat globule membrane (BM MFGM). Fraction 
4.5:1 (1) from the iatrobead column chromatography of the dual-phase 
extraction of BM MFGM (lane 3) was separated by silica gel TLC 
using chloroform:methanol (30:1) as the solvent. Lipids were fluores­
cently detected with primulin (circled bands) and carbohydrates were 
detected with orcinol in sulfuric acid. Cholesterol (lane 1) and oleic 
acid (lane 2) were run as standards. This image is representative of a 
single experiment. 
ides, particularly those containing C10:0 and C12:0 fatty 
acids, protect against foodborne gastroenteritis (Sprong 
et al., 2001) and have direct antibacterial and antiviral 
activities (Hamosh, 1991; Isaacs and Thormar, 1991; 
Hamosh et al., 1999). In addition, our previous work 
showed a direct inhibitory effect of oleic acid isolated 
from bovine colostrum on the adhesion of Cryptospo­
ridium parvum sporozoites to host cells (Schmidt and 
Kuhlenschmidt, 2008). Taken together, these data and 
the work presented here suggest that specific lipids de­
rived from milk may serve as natural inhibitors of host 
cell–microbe interactions. Future studies are needed to 
determine the potential for MFGM lipids to inhibit RV
Table 5. Comparison of the anti-infective activity of fractions 
resulting from the iatrobead dual-phase organic extraction of milk fat 
globule membrane (MFGM) isolated from buttermilk (BM) against a 
neuraminidase-sensitive rotavirus strain (OSU-RV)1 
% of MEM 
Item control 
MEM control 100 ± 10.4 
BM organic extract2 8.5 ± 1.5 
Iatrobead fractions (chloroform:methanol)
 Nonpolar (4.5:1)
 1 6.0 ± 1.0
 2 56.5 ± 3.5
 3 51.0 ± 0.0
 4 48.5 ± 5.5
 5 67.7 ± 3.0
 Polar (1:1)

 2 63 ± 0

 3 53.8 ± 16.6 
1Percentage infectivity relative to that of minimal essential medium 
(MEM) control measured using focus-forming unit assay; means ± 
SEM of duplicate wells per dose. 
2Relative to the total weight lipids isolated from the MFGM powders. 
infectivity in vivo. Isolated lipids could be fed directly to 
the animals or intact MFGM could be fed in an MFGM-
enriched diet and bioactive lipids (Hamosh, 1991; Isaacs 
and Thormar, 1991) could be released within the small 
intestine during the process of digestion. 
CONCLUSIONS 
Bovine milk appears to be a rich source of lipids with 
anti-infective properties. Lipid components associated 
with MFGM appear to contribute in large part to the 
anti-RV activity associated with the bovine MFGM, 
although further research is required to define the spe­
cific lipids responsible for this activity, as well as the 
mechanism of action. In addition, given the large quan­
tities of whey generated from buttermilk and cheese 
production (Walstra et al., 1999; USDA-NASS, 2001), 
it is worth exploring value-added uses for MFGM iso­
lated from these sources. 
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